CCChristopher Cianci

Christopher Cianci

*This is an algorithmically generated author record based on publicly available information.

Christopher Cianci has a total of 33 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Influenza Nucleoprotein: Promising Target for Antiviral Chemotherapy

    by Christopher Cianci, Samuel W Gerritz, Carol Deminie, Mark Krystal

    In the search for new anti-influenza agents, the viral polymerase has often been targeted due to the involvement of multiple conserved proteins and their distinct activities. Polymerase associates with each of the eight singled-stranded negative-sense viral RNA segments. These transcriptionally competent segments are coated with multiple copies of nucleoprotein (NP) to form the ribonucleoprotein. NP is an abundant essential protein, possessing operative and structural functions, and participating in genome organization, nuclear trafficking and RNA transcription and replication. This review examines the NP structure and function, and explores NP as an emerging target for anti-influenza drug development, focusing on recently discovered aryl piperazine amide inhibitor chemotypes.


  • Inhibition of influenza virus replication via small molecules that induce the formation of higher-order nucleoprotein oligomers

    by Samuel W. Gerritz, Christopher Cianci, Sean Kim, Bradley C. Pearce, Carol Deminie, Linda Discotto, Brian McAuliffe, Beatrice F. Minassian, Shuhao Shi, Shirong Zhu, et al.

    Influenza nucleoprotein (NP) plays multiple roles in the virus life cycle, including an essential function in viral replication as an integral component of the ribonucleoprotein complex, associating with viral RNA and polymerase within the viral core. The multifunctional nature of NP makes it an attractive target for antiviral intervention, and inhibitors targeting this protein have recently been reported. In a parallel effort, we discovered a structurally similar series of influenza replication inhibitors and show that they interfere with NP-dependent processes via formation of higher-order NP oligomers. Support for this unique mechanism is provided by site-directed mutagenesis studies, biophysical characterization of the oligomeric ligand:NP complex, and an X-ray cocrystal structure of an NP dimer of trimers (or hexamer) comprising three NP_A:NP_B dimeric subunits. Each NP_A:NP_B dimeric subunit contains two ligands that bridge two composite, protein-spanning binding sites in an antiparallel orientation to form a stable quaternary complex. Optimization of the initial screening hit produced an analog that protects mice from influenza-induced weight loss and mortality by reducing viral titers to undetectable levels throughout the course of treatment.